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We retrospectively studied 420 pharyngeal swab spec-
imens collected from Peruvian and Argentinean patients
with influenzalike illness in 2002 and 2003 for evidence of
human metapneumovirus (HMPV). Twelve specimens
(2.3%) were positive by multiple assays. Six specimens
yielded HMPV isolates. Four of the 6 isolates were of the
uncommon B1 genotype.
H
uman metapneumovirus (HMPV) has been detected in
patients with acute respiratory infection in North
America, South America, Europe, Asia, the Middle East,
Africa, and Oceania (1–7). Capitalizing on a preexisting US
Department of Defense influenza surveillance system (8),
we sought to detect and genotype HMPVin Latin American
patients in whom influenzalike illness developed.
The Study
Research was conducted on culture specimens collect-
ed from patients with influenzalike illness in Argentina and
Peru under a US Department of Defense Global Emerging
Infections System (GEIS) influenza surveillance program.
Influenzalike illness is defined as fever (temperature
>38°C) and cough or sore throat for <72 h. Under the
GEIS influenza surveillance system (8), US and interna-
tional sites collect posterior pharyngeal swabs for virus
culture from patients who meet the influenzalike illness
case definition.
Specimens were labeled with a unique specimen num-
ber and stored in cryovial boxes at –70°C until thawed for
reverse transcription–polymerase chain reaction (RT-PCR)
study. The specimens were linked by a unique laboratory
number to an electronic database with patient’s sex, age,
collection date, city, and state.
After thawing to room temperature, the 420 swab spec-
imens were screened with a 1-step RT-PCR procedure,
with the F2 primer set. Briefly, RNA from each respirato-
ry specimen was extracted with the QIAamp Viral RNA
MiniKit (Qiagen, Valencia, CA, USA). The 1-step RT-PCR
specimen screen was performed in a 100-µL reaction mix
containing 11 µL RNA, 0.4 µmol/L forward primer, 0.2
µmol/L reverse primer, 0.163 mmol/L deoxynucleoside
triphosphates, 100 U Moloney murine leukemia
virus–reverse transcriptase, 10 U RNAse inhibitor, and 2.5
U DNA polymerase in 1× DNA polymerase buffer
(PfuTurbo, Stratagene, La Jolla, CA, USA). Amplification
conditions consisted of 1 h at 42°C; 5 min at 94°C; 34
cycles of 30 s at 94°C, 30 s at 52°C, and 1 min at 72°C;
and a final extension at 72°C for 10 min. PCR products
were analyzed by electrophoresis (BioRad, Hercules, CA,
USA) in a 1.2% (wt/vol) agarose gel stained with ethidium
bromide.
Screened specimens that gave bands within 200 bp of
the expected 347-bp product were further tested with a 2-
step RT-PCR with F1-, F2-, and N-gene primer sets. The 2-
step RT-PCR was performed by using the RETROscript
Kit (Ambion, Austin, TX, USA) with heat denaturation of
RNA. PCR products were analyzed by gel electrophoresis.
Specimens were designated RT-PCR–positive if the confir-
matory N-gene primer set and at least 1 of the confirmato-
ry F-gene primer sets yielded a band within 50 bp of the
expected size (primers available from the corresponding
author) (9). 
Both 1- and 2-step RT-PCR procedures were adapted
from previous reports (9–12). With every specimen batch,
a known HMPV-positive and HMPV-negative sample was
tested in parallel to validate the run.
RT-PCR–positive specimens were further studied with
shell-vial cell culture for viable HMPV. A shell vial con-
taining a near confluent monolayer of LLC-MK2 cells
(Diagnostic Hybrids, Inc., Athens, OH, USA) was injected
with 100 µL specimen and 900 µL HMPV growth media
(1× minimum essential medium with L-glutamine and
Earle salts, 0.1% bovine albumin, 1× HEPES, 0.001%
porcine pancreatic trypsin, 0.4505 mol/L D-glucose,
10,000 U penicillin, 10 mg streptomycin, and 50 µg
amphotericin), centrifuged for 1 h at 37°C and 2,800 rpm
(1,500 × g), followed by a 37°C incubation with 5% CO2.
The cell monolayers were microscopically examined
weekly for cytopathic effect (CPE) and contamination.
Shell vials were incubated 3–4 weeks or until cell disrup-
tion occurred. Infected cell supernatant media were har-
vested each week upon cell media replacement. From an
aliquot of the infected media, RNAwas extracted and sub-
sequent RT-PCR was performed by the HMPV F2-gene 1-
step protocol. 
Sequencing was performed on the RT-PCR–positive
specimens by using Guniv primer set (available from the
corresponding author), adapted to amplify an 800- to
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trophoresed across a 1.0% agarose gel stained with ethidi-
um bromide. RT-PCR–positive products were purified
with QIAquick PCR Purification/Gel Extraction Kits
(Qiagen). Strands of the amplicons were sequenced by
automated sequencing with the Guniv primers. Big Dye
Terminator Kit v3.1 (Applied BioSystems, Foster City,
CA, USA) was used in sequencing reactions. Samples
were run on a 3730xl DNA Analyzer (Applied
BioSystems).
Alignments of partial amino acid sequences of the
HMPV G protein were generated with the ClustalW soft-
ware (National Center for Biotechnology Information,
Bethesda, MD, USA). Prototypic sequences of different
types (A and B) and subtypes (A1, A2, B1, and B2) from
the Netherlands and Canada were included in the align-
ments. Phylogenetic analysis was performed by the neigh-
bor-joining method by using MEGA 2 (University of
Pittsburgh, Pittsburgh, PA, USA). 
Specimen laboratory results were studied for demo-
graphic and temporal predictors of RT-PCR positivity by
using standard categoric data techniques. Age group cut
points were selected based on age quartiles. Exact binomi-
al 95% confidence intervals (CIs) were calculated around
prevalence statistics. Similarly, 95% CIs around odds
ratios were calculated by using logistic regression.
Analyses were performed by using SAS software version
9.1 (SAS Institute, Inc., Cary, NC, USA). 
Conclusions
We studied 420 posterior pharyngeal swab specimens
collected from January 2002 to November 2003 (Table 1).
Because of differences in clinic focus, the distribution of
influenzalike illness differed by site; children made up
higher proportions in each country (median age 11 years,
range <1–89 years, Table 2). Overall, 51% of the 302 spec-
imens for which patient’s sex was known were from male
patients. Most influenzalike illness specimens were
obtained during the coldest months (July through
September, data not shown).
Twelve (2.9%) of 420 specimens were considered
HMPV RT-PCR–positive (Table 2). All 12 positive speci-
mens were cultured on LLC-MK2 cells. Six of the 12 spec-
imens grew HMPV, and none of them showed evidence of
viral CPE before 7 days. The nonviability of the 6 remain-
ing positive specimens was likely due to the 4 freeze-thaw
cycles that occurred before LLC-MK2 cell culturing or
possibly the degradation of HMPV RNA within the speci-
mens during transport and storage. 
All 6 of the specimens that yielded an HMPV isolate in
cell culture were successfully sequenced and were used to
develop a phylogenetic tree (Figure) (13). Sequencing was
not attempted until ≈2 years after specimen collection.
This delay in sequencing and multiple freeze-thaw cycles
may explain our inability to amplify and sequence G-gene
product from the other 6 positive specimens. Sequence
data were compared to previously sequenced HMPV iso-
lates, showing a high prevalence of genotype B, with 4 iso-
lates (Peru2-2002, Peru3-2003, Peru4-2003, and
Peru5-2003) of the B1 subtype and 2 isolates (Peru1-2002
and Peru6-2003) of the B2 subtype. The high prevalence of
genotype B isolates could be due to our methodologic
approach and requires validation through other studies of
similar Peruvian specimens.
Our data suggest that HMPV is circulating in Peru.
Consistent with results of other studies, the prevalence of
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with influenzalike illness and more common among
younger children (6% in children <7 years of age, Table 1)
(1). In our study, HMPV was more often detected in male
patients and from April to June. 
Of the 12 HMPV RT-PCR–positive patients, 9 had clin-
ical reports available for review. Three children from a
small Peruvian Amazon village whose specimens were
collected within 3 days of each other were infected with
HMPV from the B1 subtype. Among these 3 children, the
youngest (3 and 4 years of age) were the most debilitated
and had the highest maximum oral temperature (39.8°C
and 39.6°C). Among the remaining 6 HMPV-positive
patients, 1 had pneumonia and 1 was hospitalized. These
data show a higher likelihood (odds ratio 4.3, 95% CI
1.3–13.8) of detecting HMPV from patients with influen-
zalike illness during the Southern Hemisphere’s autumn
(March to June) (Table 1).
HMPV genotypes B1 and B2 were detected (Figure).
Four of the 6 isolates belonged to genotype B1, which had
been uncommon in Europe, Canada, and South Africa
(7,13,15). These results represent some of first genotype
data from HMPV isolates collected in Peru. 
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